Topical Application of Bevacizumab as an Adjunct to Recurrent Pterygium Surgery
Topical Application of Bevacizumab as an Adjunct to Recurrent Pterygium Surgery
复制标题
DOI：
10.1097/ico.0b013e3182772d4e
复制
发表时间：
2013-06-01
期刊：
影响因子：
2.8
通讯作者：
Demirok, Ahmet
中科院分区：
文献类型：
--
作者：
Ozgurhan, Engin B.;Agca, Alper;Demirok, Ahmet
目的：目的：评价局部应用贝伐单抗治疗复发性翼状胬肉的临床疗效。方法：对44例复发性翼状胬肉行自体结膜移植术的患者进行前瞻性干预性研究。患者随机分为2组：研究组，术后1个月，22例患者仅接受局部贝伐珠单抗（5 mg/mL），每天4次，持续2个月;对照组，术后1个月，22例患者仅接受人工泪液，每天4次，持续2个月。患者在翼状胬肉手术后前瞻性随访6个月。主要结果的措施是翼状胬肉复发，角膜新生血管，和其他术后并发症。结果：两组之间的年龄，性别分布，偏侧性，翼状胬肉的长度，复发的数量没有统计学上的显着差异。在研究组的任何患者中均未观察到翼状胬肉复发，但在对照组的22只眼睛中有2只（9%）在术后随访期间观察到翼状胬肉复发（P = 0.244）。虽然研究组中没有患者发生角膜新生血管，但对照组中22只眼中有5只（22.7%）在术后随访期间发生了这种情况（P = 0.024）。在随访期间，在两个groups.Conclusions：局部贝伐单抗治疗复发性翼状胬肉手术切除后1个月是耐受性良好，有效地防止新生血管形成。虽然研究组的复发率较低，但无显著差异，但需要进一步的研究来支持这一结果。
Purpose: To evaluate the clinical outcomes of topical bevacizumab as adjunctive to the surgical excision for treatment of recurrent pterygium.Methods: The 44 patients who underwent recurrent pterygium excision with conjunctival autograft transplantation were enrolled in this prospective and interventional study. The patients were randomized in 2 groups: study group, 1 month after surgery, 22 patients received only topical bevacizumab (5 mg/mL) 4 times daily for 2 months; control group, 1 month after surgery, 22 patients were administered only an artificial tear 4 times daily for 2 months. Patients were prospectively followed for 6 months after pterygium surgery. The main outcome measures were pterygium recurrence, corneal neovascularization, and other postoperative complications.Results: No statistically significant differences were observed between the 2 groups in terms of age, gender distributions, laterality, length of pterygium, and number of recurrence. A pterygium recurrence was not noted in any patients in the study group but was noted in 2 of 22 eyes (9%) in the control group during the follow-up after surgery (P = 0.244). Although none of the patients developed corneal neovascularization in the study group, 5 of 22 eyes (22.7%) developed this condition in the control group during the follow-up after surgery (P = 0.024). No serious complications were observed during the follow-up period in both the groups.Conclusions: Topical bevacizumab therapy 1 month after surgical excision of recurrent pterygium is well tolerated and effective to prevent neovascularization. Although the recurrence rate is lower in the study group without significant difference, further studies are required to support this result.